A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis

Sponsor
Janssen-Cilag Pharma GmbH
Study ID
NCT07606339
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to evaluate how long a participant keeps taking guselkumab or continues with their treatment plan without stopping (treatment persistence) in participants with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are inflammatory bowel diseases, a group of inflammatory conditions of the colon and small intestine.

Key Dates

First listed
May 26, 2026
Start date
Jun 10, 2026
Status verified
Aug 2026
Primary completion
Jun 10, 2029
Completion
Jun 10, 2029

Study Design

Enrollment
35 participants (estimated)

Arms

  • Arm: Moderate-to-Severe Ulcerative Colitis (UC) or Crohn's Disease (CD)
    Participants with confirmed diagnosis of moderate to severe crohn's disease (CD) or ulcerative colitis (UC) treated with guselkumab in routine clinical practice will be enrolled. No drug will be provided as a part of this study. Only data available from clinical practice and medical records will be collected within this study.

Primary Outcome Measure

Persistence with Guselkumab Treatment [ Time Frame: Up to Week 96 ]

Central Contacts

Find similar trials

Nationwide
Crohn's disease trialsGastroenterology trialsInflammatory bowel disease trialsAutoimmune disease trials

Related Studies